
Office of Communications
and Public Liaison (OCPL)
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Phone: 301-496-1752
nianews3@mail.nih.gov
NIA is the lead Federal agency for supporting and conducting Alzheimer's disease research. For NIA background information on this topic see:
See NIA research news related to Alzheimer's disease below.
A new analysis of head injuries among World War II veterans links serious head injury in early adulthood with Alzheimer's disease (AD) in later life. The study, by researchers at Duke University and the National Institute on Aging (NIA...
Nasal administration of synthetic beta amyloid peptide reduces potentially damaging Alzheimer's disease-like plaques in the brains of test mice and may one day be tested in clinical trials for its ability to vaccinate against plaque...
The National Institute on Aging (NIA) is launching a clinical trial to determine whether treatment with certain nonsteroidal anti-inflammatory drugs (NSAIDs) will slow cognitive and clinical decline in patients with Alzheimer's disease...
A low-dose regimen of the steroid prednisone, an anti-inflammatory drug, is not effective in the treatment of Alzheimer's disease (AD), according to findings from a new clinical trial. The report, one of the first from a number of...
Scientists have succeeded in producing a hallmark of Alzheimer's disease in a laboratory animal model. The much-anticipated transgenic mouse model is genetically-engineered with the human gene coding for a form of the brain protein tau...
Researchers supported by the National Institute on Aging (NIA) have discovered a novel gene, which when mutated is responsible for familial British dementia (FBD), a rare inherited disease that causes progressive dementia like that seen in...
Researchers have cracked part of the code for an important gene function in familial Alzheimer's disease (FAD), an early-onset type of AD. Alzheimer's disease is the most common cause of dementia. Working with cells in culture that...
The National Institute on Aging (NIA) is launching a nationwide treatment study targeting individuals with mild cognitive impairment (MCI), a condition characterized by a memory deficit, but not dementia. The start-up of the trial,...
1. What is Mild Cognitive Impairment? Mild cognitive impairment (MCI) is a condition characterized by memory impairment with otherwise unaffected cognitive functioning. 2. How can MCI be distinguished from normal forgetfulness? Normal...
University of Pittsburgh researchers supported by the National Institute on Aging (NIA) and the National Cancer Institute report in the March 1998 issue of Nature Genetics the discovery of a new genetic association with Alzheimer's...